Core Viewpoint - Sunflower is planning a significant asset restructuring by acquiring controlling stakes in two companies, aiming to expand its business into the semiconductor materials sector while consolidating its pharmaceutical operations [1][9]. Group 1: Acquisition Details - The company announced plans to acquire the controlling stake in Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. through share issuance and/or cash payment [1]. - The transaction is expected to constitute a major asset restructuring and will not lead to a change in the actual controller of the company [1]. - The stock will be suspended from trading starting September 8, 2025, with the transaction plan to be disclosed within 10 trading days [1]. Group 2: Company Background and Business Transition - Sunflower, established in 2005, initially focused on solar energy products and has undergone several transitions, including a name change to Zhejiang Sunflower Health Technology Co., Ltd. in 2020, focusing on pharmaceutical products [7][8]. - The company has previously attempted to diversify into various sectors, including pharmaceuticals and high-tech materials, but faced challenges due to market fluctuations and technical issues [8]. - The current acquisition is seen as another attempt to pivot towards high-growth sectors, particularly in semiconductor materials, which may help reverse the declining performance in its existing business segments [15]. Group 3: Financial Performance - In the first half of 2025, the company reported revenue of approximately 144 million yuan, a year-on-year decrease of 8.33%, and a net profit of only 1.16 million yuan, down 35.68% [12]. - The financial struggles have prompted the company to explore frequent cross-industry transformations, reflecting challenges in its current business operations, especially in the pharmaceutical sector [12][14]. - The company aims to leverage the high growth potential of the semiconductor materials industry to improve its financial performance [15].

Core Viewpoint - Sunflower (300111) is attempting another cross-industry acquisition by planning to acquire a controlling stake in Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. [1][2] Group 1: Acquisition Details - The acquisition will be executed through the issuance of shares and/or cash payments, along with a plan to raise supporting funds [1] - Following the announcement, Sunflower's stock was suspended from trading to ensure fair information disclosure and protect investor interests [1] - Prior to the announcement, Sunflower's stock price surged by 11.96% on September 5, closing at 4.96 yuan per share, with a trading volume of 6.03 billion yuan and a turnover rate of 9.93% [1] Group 2: Business Focus - Sunflower's main business focuses on the pharmaceutical sector, including the research, production, and sales of anti-infection, cardiovascular, and digestive system drugs [2] - The acquisition of Xipu Materials represents a cross-industry move, which may involve higher integration risks due to the significant difference in business operations [2] Group 3: Previous Attempts and Financial Performance - Sunflower previously attempted a cross-industry investment in March 2024, which ultimately failed due to the lack of technical progress from the partner [3] - The company reported a decline in both revenue and net profit for the first half of the year, with revenue of approximately 144 million yuan, down 8.33%, and a net profit of approximately 1.16 million yuan, down 35.68% [3]